Medical Policy

Effective Date:04/01/2012 Title:Dorsal Column Stimulator for Pain
Revision Date:07/01/2020 Document:BI348:00
CPT Code(s):63650, 63655, 63685, 63688, A4290, C1767, C1816, C1820, E0745, L8680-L8689
Public Statement

Effective Date:

a)    This policy will apply to all services performed on or after the above revision date which will become the new effective date.

b)    For all services referred to in this policy that were performed before the revision date, contact customer service for the rules that would apply.

1)    Spinal cord stimulation (dorsal column) requires pre-authorization.

2)    Spinal cord stimulation is used to treat severe pain in the limbs and back that has not responded to all other forms of therapy.

Medical Statement

1.    Dorsal column stimulators (DCS) are covered  with preauthorization for the management of members with chronic pain that has not responded to all other forms of therapy*** and is due to:

a)    Failed back surgery syndrome with low back pain and significant radicular pain (M96.1), or

b)    Complex regional pain syndrome (also known as reflex sympathetic dystrophy), (G90.50 – G90.59), or

c)    Inoperable chronic ischemic limb pain secondary to peripheral vascular disease (I70.221 – I70.229, I70.321 – I70.329, I70.421 – I70.429, I70.521 – I70.529, I70.621 – I70.629, I70.721 – I70.729), or

d)    Members with documented metastatic malignant disease, who have a life expectancy of at least six months, is covered when above criteria are met, (psychological testing would not be required)
AND the member meets all of the following criteria:

·         Member experienced significant pain reduction (50% or more) with a 3- to 7-day trial of percutaneous spinal stimulation.  (A trial of percutaneous spinal stimulation is considered medically necessary for members who meet the below-listed criteria, in order to predict whether a dorsal column stimulator will induce significant pain relief.), and

·         There is documented pathology, i.e., an objective basis for the pain complaint, and 

·         Other more conservative methods of pain management have been tried and failed, and 

·         Member does not have any untreated existing drug addiction problems (per American Society of Addiction Medicine (ASAM) guidelines), and 

·         Member has obtained psychiatric clearance, and 

·         Member has predominantly radiating extremity pain.

2.    Revision, replacement or removal of spinal cord stimulators and their components are covered services.  Replacement components require preauthorization.

3.    Neuromuscular stimulators are not addressed by this policy; see BI116.

 

*** “Lack of response to all other forms of therapy” should include the preferred non-pharmacologic treatment modalities, the preferred non-opioid pharmacologic interventions and clinically appropriate procedural interventions described in detail in BI566 (Opioid Therapy for Chronic Pain).  G Trial/failure of opioids is not a requirement for a dorsal column stimulator for pain.

Codes Used In This BI:

63650

Implant neuroelectrodes

63655

Implant neuroelectrodes

63685

Insrt/redo spine n generator

63688

Revise/remove neuroreceiver

A4290

Sacral nerve stimulation test lead, each

C1767

Generator, Neurostimulator (implantable), nonrechargeable

C1816

Receiver and/or transmitter, Neurostimulator (implantable)

C1820

Generator, Neurostimulator (implantable), w/rechrgbl battery & charging system

E0745

Neuromuscular stimulator, electronic shock unit

L8680

Implantable neurostim electrode, each

L8681

Patient program (external) for use w/implantable progrmbl neurostim pulse genrtr, rplcmnt only

L8682

Implantable neurostim radiofreq recvr

L8683

Radiofreq transmit (external) for use w/implantable neurostim radiofreq recvr

L8684

Radiofreq transmit (external) for use w/implantable sacral root neurstmltr recvr for bowel & bladder mgmt, rplcmnt

L8685

Implantable neurostim pulse generator, single array, rechargeable, includes extension

L8686

Implantable neurostim pulse generator, single array, nonrechargeable, includes extension

L8687

Implantable neurostim pulse generator, dual array, rechargeable, includes extension

L8688

Implantable neurostim pulse generator, dual array, nonrechargeable, includes extension

L8689

External recharging system for battery (Internl) for use w/implantable neurostim, rplcmnt only

Limits

1)    DCS is considered experimental and investigational for the management of members with other chronic non-malignant pain (e.g., headache, cephalgia, occipital neuralgia, intercostal neuralgia, trigeminal neuralgia, phantom limb syndrome, inguinal pain, and post-herpetic neuralgia), or spasticity because its effectiveness for these indications has not been established.

2)    Cervical spinal cord stimulation for the treatment of members with cervical trauma, disc herniation, or failed cervical spine surgery syndrome, presenting with arm pain, neck pain, or Cervicogenic headache, is considered experimental and investigational because its effectiveness for these indications has not been established.

Reference

1.     Kemler MA, De Vet HC, Barendse GA, et al. (2004) the effect of spinal cord stimulation in patients with chronic reflex sympathetic dystrophy: two years` follow-up of the randomized controlled trial. Annals Neurology 2004; 55(1):13-8.

2.     Kemler MA, De Vet HC, Barendse GA, et al. (2004) the effect of spinal cord stimulation in patients with chronic reflex sympathetic dystrophy: two years’ follow-up of the randomized controlled trial. Ann Neurol 2004; 55(1):13-8.

3.     Kemler MA, de Vet HC, et al. (2008) Effection of spinal cord stimulation for chronic complex regional pain syndrome Type I: five-year final follow-up of patients in a randomized controlled trial. J Neurosurg, 2008; 108:292-8.

4.     Klomp HM, Spincemaille GH, Steyerberg EW, et al.(1999) Spinal cord stimulation in critical limb ischemia: a randomized trial. Lancet 1999; 353(9158):1040-4.

5.     Lapenna E, Papati D, et al.(2006) Spinal cord stimulation for patients with refractory angina and previous coronary surgery. Ann Thor Surg, 2006; 82:1704-8.

6.     Mailis-Gagnon A, Furlan AD, Sandoval JA, et al.(2004) Spinal cord stimulation for chronic pain. The Cochrane Database Systematic Reviews, Issue 3, Art. No. CD003783.pub2; 2004.

7.     Meyerson BA. (2001) Neurosurgical approaches to pain treatment. Acta Anaesthesiol Scand 2001; 45:1108-13.

8.     North R, Shipley J, et al.(2007) Practice parameters for the use of spinal cord stimulation in the treatment of chronic neuropathic pain. Pain Med, 2007; 8:S200-S275.

9.     North RB, Calkins SK, Campbell DS, et al. (2003) Automated, patient-interactive, spinal cord stimulator adjustment: a randomized controlled trial. Neurosurgery 2003; 52(3):572-80.

10. North RB, et al. (1993) Sperm function assays and their predictive value for fertilization outcome in IVF therapy: a meta-analysis. Neurosurg 1993; 32:384-395.

11. North RB, Kidd DH, Lee MS et al. (1994) a prospective, randomized study of spinal cord stimulation versus reoperation for failed back surgery syndrome: initial results. Stereotact Funct Neurosurg 1994; 62(1-4):267-72.

12. The British Pain Society. (2005) Spinal cord stimulation for the management of chronic pain. Recommendations for best clinical practice. http://britishpainsociety.org, accessed Feb 2007.

13. Turner JA, Loeser JD, Bell KG.(1995) Spinal cord stimulation for chronic low back pain: a systematic literature synthesis. Neurosurgery 1995; 37(6):1088-96.

14. Ubbink DT, Vermeulen H. (2003) Spinal cord stimulation for non-reconsdtructable chronic critical leg ischemia. The Cochrane Database Systematic Reviews 2003, Issue 3, Art NO. CD004001.

15. Arkansas BlueCross BlueShield, Coverage Policy Manual; Spinal Cord Neurostimulation for Treatment of Intractable Pain.

Addendum:

Effective 01/01/2017: Removed the following codes from Codes Used in This BI section: 63661 – 63664, 63688. Codes no longer referenced in BI.

Application to Products
This policy applies to all health plans administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet. Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) for those plans insured by QualChoice. In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC, the SPD or EOC, as applicable, will prevail. State and federal mandates will be followed as they apply.

Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.